Edit Target: 258
Cannabidiolic acid (CBDA) is the acidic precursor of cannabidiol (CBD) found in Cannabis sativa.
- Note that although CBDA shares some pharmacological properties with CBD, its profile can differ due to its carboxylic acid group, which may affect its bioavailability, receptor binding, and overall cellular uptake.
Cannabidiolic acid (CBDA) shows promise in modulating several pathways that are relevant to cancer biology—including COX-2 inhibition, PPARγ activation, apoptosis induction, and anti-inflammatory effects. In parallel, CBDA may offer additional benefits such as anti-emetic, anxiolytic, and potential neuroprotective effects. However, the current body of research is largely preclinical.
CBDA is often found in raw cannabis plants and does not undergo decarboxylation like its more well-known counterpart cannabidiol (CBD).
Unlike the tetrahydrocannabinol (THC) found in cannabis, CBDA is non-psychoactive. This means it does not cause the "high" or altered state of mind commonly associated with cannabis use.
CBDA does not directly bind to the primary cannabinoid receptors (CB1 and CB2) in the brain that are responsible for psychoactive effects.
Pathways:
-CBDA may modulate receptors beyond the classical CB1 and CB2, such as transient receptor potential (TRP) channels (e.g., TRPV1) and possibly the orphan receptor GPR55, thereby influencing cell signaling, calcium homeostasis, and related pathways.
-Inhibition of cyclooxygenase enzymes (COX)
-Mitochondrial dysfunction and the activation of caspases
-Modulation of the PI3K/Akt Pathway
-Affect the MAPK family of pathways, including ERK, JNK, and p38 kinases
-Modulating matrix metalloproteinases (MMPs)
-As an antioxidant (or under some conditions a pro-oxidant)